ECSP024218A - Metodo de tratamiento de enfermedades o condiciones de desmielinizacion - Google Patents

Metodo de tratamiento de enfermedades o condiciones de desmielinizacion

Info

Publication number
ECSP024218A
ECSP024218A EC2002004218A ECSP024218A ECSP024218A EC SP024218 A ECSP024218 A EC SP024218A EC 2002004218 A EC2002004218 A EC 2002004218A EC SP024218 A ECSP024218 A EC SP024218A EC SP024218 A ECSP024218 A EC SP024218A
Authority
EC
Ecuador
Prior art keywords
treatment
conditions
compounds
useful
diseases
Prior art date
Application number
EC2002004218A
Other languages
English (en)
Inventor
David Rampe
Michel P Rathbone
Craig P Smith
Margaret Petty
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of ECSP024218A publication Critical patent/ECSP024218A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

N-(PIRIDINIL)-1 H-indol-1- amina de fórmula I provee una combinación única de propiedades de bloqueo para los canales de potasio y sodio. Estos compuestos son útiles para el tratamiento de la Desmielinización y sus condiciones tales como Esclerosis Múltiple, daños en la médula espinal, daño traumático en el cerebro y parálisis. Los compuestos son útiles también para la rehabilitación de apoplejías, tratamiento para la irritación y disfunción de la vejiga, y tratamiento para dolor neuropático e inducido por chemokine.
EC2002004218A 2001-02-15 2002-02-15 Metodo de tratamiento de enfermedades o condiciones de desmielinizacion ECSP024218A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26884601P 2001-02-15 2001-02-15

Publications (1)

Publication Number Publication Date
ECSP024218A true ECSP024218A (es) 2003-09-24

Family

ID=23024747

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2002004218A ECSP024218A (es) 2001-02-15 2002-02-15 Metodo de tratamiento de enfermedades o condiciones de desmielinizacion

Country Status (39)

Country Link
US (10) US6967210B2 (es)
EP (1) EP1368031A2 (es)
JP (3) JP2004518711A (es)
KR (3) KR100951540B1 (es)
CN (2) CN100522164C (es)
AP (1) AP1749A (es)
AR (1) AR035750A1 (es)
AU (3) AU2002247200B9 (es)
BR (1) BR0207272A (es)
CA (1) CA2438712A1 (es)
CO (1) CO5390085A1 (es)
CR (1) CR7023A (es)
CZ (1) CZ20032172A3 (es)
EA (2) EA012409B1 (es)
EC (1) ECSP024218A (es)
EE (1) EE200300363A (es)
GB (1) GB0119435D0 (es)
HK (1) HK1080361B (es)
HR (1) HRP20030652A2 (es)
HU (1) HUP0303203A3 (es)
IL (2) IL157341A0 (es)
MA (1) MA26152A1 (es)
ME (1) MEP21208A (es)
MX (1) MXPA03006110A (es)
MY (1) MY157745A (es)
NO (1) NO20033622L (es)
NZ (4) NZ544720A (es)
OA (1) OA12549A (es)
PA (1) PA8540101A1 (es)
PE (1) PE20040175A1 (es)
PL (1) PL363638A1 (es)
SG (1) SG134170A1 (es)
SK (1) SK10392003A3 (es)
TR (4) TR200301330T2 (es)
TW (1) TWI325319B (es)
UA (2) UA80394C2 (es)
WO (1) WO2002064126A2 (es)
YU (1) YU62903A (es)
ZA (1) ZA200306124B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
BR0317606A (pt) * 2002-12-20 2005-11-29 Dynogen Pharmaceuticals Inc Métodos de tratamento de distúrbios não dolorosos da bexiga urinária que usam moduladores de canal de cálcio de subunidade (alfa)2(delta)
AU2004207010A1 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
US20040198822A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmacueticals, Inc. Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators
GT200500063A (es) * 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
GB0510164D0 (en) * 2005-04-28 2005-06-22 Paradigm Therapeutics Ltd Ion channel
FR2892022B1 (fr) * 2005-10-19 2008-01-04 Urogene Sa Traitement des symptomes de l'irritation de la vessie
FR2892021B1 (fr) * 2005-10-19 2008-01-04 Urogene Traitement de l'incontinence urinaire d'effort et mixte
US8420593B1 (en) * 2006-06-16 2013-04-16 Landon C. G. Miller Compositions and methods for regulating membrane potential
DE102008044844B4 (de) * 2008-08-28 2018-08-30 Siemens Healthcare Gmbh Verfahren zur Ermittlung einer Schwächungskarte zur Verwendung in der Positronenemissionstomographie und von Homogenitätsinformationen des Magnetresonanzmagnetfeldes
KR101862539B1 (ko) * 2010-03-26 2018-05-31 가부시키가이샤 한도오따이 에네루기 켄큐쇼 반도체 장치
US20130184316A1 (en) * 2010-07-15 2013-07-18 Andrew Hornstein Methods for diagnosing and treating concussive disorders
EP2995305B1 (en) * 2011-01-28 2020-03-04 Acorda Therapeutics, Inc. Use of potassium channel blockers to treat cerebral palsy
TWI592156B (zh) * 2011-10-04 2017-07-21 艾可達醫療公司 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
EP3727587A4 (en) 2017-12-22 2022-02-23 Massachusetts Institute Of Technology COMPOSITIONS AND METHODS FOR THERAPY OF WILLIAMS SYNDROME (WS)
CN116723870A (zh) * 2021-01-20 2023-09-08 拉什大学医学中心 球形细胞脑白质营养不良症或克拉伯病的改良治疗

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880822A (en) * 1987-04-24 1989-11-14 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyridinyl)-1H-indol-1-amines
US4970218A (en) * 1987-04-24 1990-11-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyridinyl)-1H-indol-1-amines
ATE115143T1 (de) * 1987-04-24 1994-12-15 Hoechst Roussel Pharma N-(pyridinyl)-1h-indol-1-amine, verfahren zu deren herstellung und ihre verwendung als arzneimittel.
IL95251A (en) * 1989-08-02 1996-08-04 Hoechst Roussel Pharma 2,3-Dihydro-1- (pyridinylamino) - indoles, a method for their preparation and use as drugs
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
DE4325491A1 (de) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
US5459274A (en) * 1994-05-13 1995-10-17 Hoechst-Roussel Pharmaceuticals Inc. Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines
US5565475A (en) * 1994-11-08 1996-10-15 Muhlhauser; Mark A. Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
EP0731108A1 (en) * 1995-03-10 1996-09-11 Boehringer Mannheim Gmbh Method of manufacturing a therapeutic agent for the regeneration of oligodendrocytes
FR2754147B1 (fr) 1996-10-03 2000-02-04 Mbh Technologies Sa Installation et procede pour le traitement de carcasses
DK1056754T3 (da) * 1998-01-29 2004-02-16 Bristol Myers Squibb Co Phosphatderivater af diaryl-1,3,4-oxadiazolon
WO2001004091A1 (en) * 1999-07-09 2001-01-18 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions

Also Published As

Publication number Publication date
HRP20030652A2 (en) 2005-06-30
JP2010120958A (ja) 2010-06-03
US20050234105A1 (en) 2005-10-20
NZ544720A (en) 2007-08-31
SG134170A1 (en) 2007-08-29
CO5390085A1 (es) 2004-04-30
HUP0303203A3 (en) 2007-11-28
US7230015B2 (en) 2007-06-12
EA012409B1 (ru) 2009-10-30
US20050159456A1 (en) 2005-07-21
WO2002064126A3 (en) 2003-02-20
US7534803B2 (en) 2009-05-19
US6967210B2 (en) 2005-11-22
JP2009185045A (ja) 2009-08-20
CR7023A (es) 2003-11-17
US20090209594A1 (en) 2009-08-20
AU2002247200B2 (en) 2007-12-13
PL363638A1 (en) 2004-11-29
TR200800693T2 (tr) 2008-07-21
IL157341A (en) 2010-11-30
AU2008201179A1 (en) 2008-04-03
OA12549A (en) 2006-06-05
US20090270458A1 (en) 2009-10-29
AP2003002834A0 (en) 2003-09-30
US20030105150A1 (en) 2003-06-05
CN100522164C (zh) 2009-08-05
UA80394C2 (en) 2007-09-25
NO20033622D0 (no) 2003-08-14
AU2009238332A1 (en) 2009-12-10
ZA200306124B (en) 2004-11-08
HUP0303203A2 (hu) 2003-12-29
MXPA03006110A (es) 2005-07-01
BR0207272A (pt) 2004-02-10
CZ20032172A3 (cs) 2004-01-14
PE20040175A1 (es) 2004-03-29
SK10392003A3 (sk) 2004-01-08
TWI325319B (en) 2010-06-01
CN1529598A (zh) 2004-09-15
EP1368031A2 (en) 2003-12-10
IL157341A0 (en) 2004-02-19
HK1080361A1 (en) 2006-04-28
KR20090005255A (ko) 2009-01-12
HK1080361B (zh) 2009-10-30
NO20033622L (no) 2003-10-06
US20090209595A1 (en) 2009-08-20
US20090281147A1 (en) 2009-11-12
US20040157888A1 (en) 2004-08-12
AU2002247200B9 (en) 2008-07-10
US20040157889A1 (en) 2004-08-12
EA200300882A1 (ru) 2003-12-25
CN1679564A (zh) 2005-10-12
KR20090005254A (ko) 2009-01-12
TR200800691T2 (tr) 2008-03-21
KR100951540B1 (ko) 2010-04-09
NZ556697A (en) 2009-01-31
TR200301330T2 (tr) 2004-12-21
MA26152A1 (fr) 2004-07-01
KR100951542B1 (ko) 2010-04-09
AU2008201179B2 (en) 2009-08-20
MY157745A (en) 2016-07-15
TR200800692T2 (tr) 2008-03-21
WO2002064126A2 (en) 2002-08-22
EA011319B1 (ru) 2009-02-27
EE200300363A (et) 2003-10-15
US20060025452A1 (en) 2006-02-02
JP2004518711A (ja) 2004-06-24
GB0119435D0 (en) 2001-10-03
PA8540101A1 (es) 2003-09-05
AR035750A1 (es) 2004-07-07
UA88773C2 (ru) 2009-11-25
EA200600896A1 (ru) 2006-08-25
US7179821B2 (en) 2007-02-20
MEP21208A (en) 2010-06-10
NZ527011A (en) 2005-07-29
NZ539159A (en) 2006-11-30
KR20040014459A (ko) 2004-02-14
YU62903A (sh) 2006-05-25
CA2438712A1 (en) 2002-08-22
AP1749A (en) 2007-06-13

Similar Documents

Publication Publication Date Title
ECSP024218A (es) Metodo de tratamiento de enfermedades o condiciones de desmielinizacion
CU23029A3 (es) Analogos sustituidos del benzopirano para el tratamiento de la inflamacion
AR028824A1 (es) Compuestos antagonistas npy-5 y su uso en la manufactura de medicamentos.
EA200300566A1 (ru) Применение cci-779 в качестве противоопухолевого средства
NO20063064L (no) Ny anvendelse av peptidforbindelser for behandling av sentralneurotisk smerte
ATE206409T1 (de) N-(1-alkyl-5-phenyl-2,3,4,5-tetrahydro-1-h- benzo(b)(1,5)-diazepin-3-yl)-acetamide
DK1109817T3 (da) Phosphohalogenhydriner, deres fremstilling og anvendelse
ES2186550B2 (es) Nuevos derivados de oxazolidinonas como antibacterianos.
DE60325377D1 (de) Motilidverbindungen
SE0101322D0 (sv) Novel compounds
DE60129829D1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
ITMI20030573A1 (it) Composti ad azione nootropica, loro preparazione,
ECSP034598A (es) Compuesto lactamico
CY1107158T1 (el) Νεα παραγωγα της ισοκινολινης, η μεθοδος παρασκευης τους και η χρηση τους για τη θεραπεια των διαταραχων του μελατονινεργικου συστηματος
CY1105345T1 (el) Φαινυλαλκινια
NO20026219L (no) Forbindelser for behandling av svekket fundisk relaksasjon
PL372769A1 (en) Cyanoguanidine prodrugs
GB0207653D0 (en) Methods of using lamellar bodies for therapeutic purposes
ITGE20020050A0 (it) Procedimento per il trattamento di filati mediante agugliatura.
BR0208593A (pt) método para o tratamento de um mamìfero, composto, e, composição farmacêutica
UY27206A1 (es) Método de tratamiento de condiciones o enfermedades desmielinizantes
UY26997A1 (es) Alquinilamidas y aplicaciones terapéuticas de las mismas
EA200200750A1 (ru) Новое терапевтическое применение еноксапарина
DE60235538D1 (de) Glycopeptid-antibiotika
BRPI0409691A (pt) compostos de fosfonato tendo atividade imuno-moduladora